Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pexa-Vec + Ipilimumab in Advanced Solid Tumors
NCT02977156Phase 1Completed
- Sponsor
- Centre Léon Bérard
- Start
- Jan 2017
- Primary completion
- Apr 2022
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vaccinia granulocyte-macrophage colony-stimulating factor recombinant virus in solid tumor, sponsored by Centre Léon Bérard. Primary endpoints: Dose Limiting Toxicities at 5 weeks and Objective Response Rate at 3 months. Started Jan 2017; status: completed.
02
Drugs
vaccinia granulocyte-macrophage colony-stimulating factor recombinant virus
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02977156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02977156.